Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (NASDAQ: PAVM) generates news across medical devices, diagnostics, and digital health, reflecting its role as a diversified, commercial-stage medical technology company. Its news flow often covers developments at the parent company level as well as at its subsidiaries, Lucid Diagnostics Inc. and Veris Health Inc., which focus on cancer prevention diagnostics and digital cancer care.
Investors following PAVM news can expect updates on corporate actions, such as the announced 1-for-30 reverse stock split intended to help the company meet Nasdaq’s minimum bid price requirement and maintain its listing on the Nasdaq Capital Market. Company communications also highlight business updates, quarterly financial results, and information on balance sheet and capital structure decisions, often furnished through press releases and Form 8-K filings.
News related to Lucid Diagnostics, a subsidiary of PAVmed, frequently focuses on the commercialization and clinical performance of the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Recent announcements have described large real-world datasets on non-endoscopic esophageal precancer detection, Medicare coverage processes, and participation in medical and investor conferences.
Updates involving Veris Health typically center on the Veris Cancer Care Platform and its deployment in clinical settings. For example, PAVmed and Veris have reported the launch of the commercial phase of a long-term strategic partnership with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, focused on enhancing personalized cancer care for patients undergoing systemic cancer therapy.
This PAVM news page brings together these types of announcements, allowing readers to track financial disclosures, technology and platform milestones, regulatory and reimbursement developments, strategic partnerships, and corporate governance actions over time.
Lucid Diagnostics (Nasdaq: LUCD) successfully completed its first major directly-contracted #CheckYourFoodTube Precancer Testing Event in partnership with the Fort Worth Fire Department (FWFD) and Front Line Mobile Health. Nearly 200 firefighters underwent testing using Lucid's EsoGuard® Esophageal DNA test and EsoCheck® Esophageal Cell Collection Device.
FWFD Fire Chief Jim Davis emphasized the importance of early detection, citing his personal loss to esophageal cancer. Lucid's President and COO, Shaun O'Neil, highlighted the potential for directly contracting with self-insured entities to contribute to long-term revenue growth. The event garnered local media coverage and addressed the increased risk of esophageal cancer among firefighters.
Lucid Diagnostics (Nasdaq: LUCD) has released new real-world data from its ENVET-BE study, demonstrating the clinical utility of the EsoGuard® Esophageal DNA test as a non-invasive triage tool for detecting esophageal precancer and cancer. The study showed that patients triaged to invasive upper endoscopy (EGD) following a positive EsoGuard test had a 2.4-fold increase in positive yield compared to screening EGD alone in at-risk patients.
Key findings include:
- EGD confirmed Barrett's Esophagus (BE) in 50 out of 199 patients who received a positive EsoGuard result
- Post-triage EGD yield was 25%, compared to the expected 11% yield of EGD as a standalone screening tool
- Results support the use of EsoGuard as an alternative to EGD for esophageal precancer testing, potentially increasing compliance with screening guidelines and reducing esophageal cancer deaths
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in two upcoming investor conferences. The company will attend the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12-13, 2024. Additionally, Lucid will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 1:30 PM ET.
Investors can access the live and archived webcast of the Canaccord Genuity fireside chat through the provided link or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the live broadcast.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for August 13, 2024, at 8:30 AM ET. During the call, Chairman and CEO Lishan Aklog, M.D., will provide an overview of the company's operations and growth strategy, while President and CFO Dennis McGrath will discuss second quarter 2024 financial results.
Investors can access the webcast through PAVmed's website or join the conference call by dialing 1-800-836-8184 (U.S.) or 1-646-357-8785 (international). The call name is "PAVmed Business Update". A 30-day replay will be available on the company's website following the call.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company, has announced a business update conference call and webcast scheduled for August 12, 2024, at 8:30 AM ET. The event will feature:
- A business update and overview of operations by CEO Lishan Aklog, M.D.
- Discussion of the company's growth strategy
- Presentation of Q2 2024 financial results by CFO Dennis McGrath
Interested parties can access the webcast via the investor relations section of luciddx.com. For telephone access, U.S. callers should dial 1-800-836-8184, while international listeners should use 1-646-357-8785. The conference call name is "Lucid Diagnostics Business Update". A 30-day replay will be available on the company's website after the call.
Lucid Diagnostics Inc. (Nasdaq: LUCD) reported a record-breaking quarter for its EsoGuard® Esophageal DNA test volume. In Q2 2024, the company performed 3,174 tests, marking a 31% increase from Q1. This growth is attributed to expanded awareness and demand for EsoGuard esophageal precancer testing across various healthcare settings.
CEO Lishan Aklog emphasized the company's focus on increasing access to EsoGuard testing. Lucid expects to release full Q2 2024 results in mid-August. Additionally, the company held a productive meeting with CMS Medicare Administrative Contractor Palmetto GBA's Molecular Diagnostics Program (MolDX), which included key executives and medical experts in gastroenterology.
Lucid Diagnostics (Nasdaq: LUCD), a company focused on cancer prevention medical diagnostics, has launched a newly redesigned corporate website (www.luciddx.com) as announced on July 11, 2024. This improved platform aims to provide an enhanced user experience for patients, healthcare professionals, investors, and other stakeholders. According to Jenna Mowatt, Vice President of Marketing and Communications, the website is designed to reflect the company's mission to prevent esophageal cancer and showcase its innovative technologies through a modern design and comprehensive content. Lucid Diagnostics encourages visitors to explore the new website for more information.
Lucid Diagnostics announced positive results from its ESOGUARD BE-1 clinical validation study for EsoGuard, a test for detecting esophageal precancer. The study showed an 87.5% sensitivity and a 98.6% negative predictive value (NPV). The study was conducted across multiple international centers, including major U.S. and European institutions. The results support the upcoming Medicare LCD pre-submission and ongoing commercial payor engagements. The study involving 93 subjects confirmed the test's efficiency and safety, potentially making esophageal cancer screening more accessible and effective.
PAVmed's subsidiary, Veris Health, has launched a pilot program in collaboration with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). This program marks the first enrollment of patients on the Veris Cancer Care Platform, a comprehensive digital tool designed to enhance personalized cancer care. The platform integrates remote physiological data collection, symptom reporting, telehealth, and electronic health record capabilities. Cancer patients utilize the VerisBox and a patient portal for seamless data transmission and monitoring. Veris is also developing an implantable physiological monitor to complement the platform. The collaboration aims to improve early complication detection, reduce unplanned hospitalizations, and increase patient satisfaction.
Lucid Diagnostics announced that its EsoGuard® Esophageal DNA test has been used on the 4,000th firefighter as part of the #CheckYourFoodTube Precancer Testing Event, held by Mass General Brigham physicians and Boston Firefighters Local 718. The event aims to address the elevated risk of esophageal cancer among firefighters. This milestone event is part of Lucid Diagnostics' broader strategy to increase test volumes and highlights the importance of early cancer detection. Firefighters face a 62% higher risk of developing esophageal cancer and a 39% higher risk of dying from it. Estimates from the American Cancer Society suggest 22,370 new cases and 16,130 deaths from esophageal cancer in 2024.
FAQ
What is the current stock price of Pavmed (PAVM)?
What is the market cap of Pavmed (PAVM)?
